Except for historical information contained in this report, the matters
discussed are forward-looking statements that involve risks and uncertainties.
When used in this report, words such as "anticipates", "believes", "could",
"estimates", "expects", "may", "plans", "potential" and "intends" and similar
expressions, as they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are based on the
beliefs of the Company's management, as well as assumptions made by and
information currently available to the Company's management. Among the factors
that could cause actual results to differ materially are the following: the
effect of business and economic conditions, including the current COVID-19
pandemic which has already adversely affected operating results; the effect of
the dramatic changes taking place in IT and healthcare; the impact of
competitive procedures and products and their pricing; medical insurance
reimbursement policies; unexpected manufacturing or supplier problems;
unforeseen difficulties and delays in product development programs; the actions
of regulatory authorities and third-party payers in the United States and
overseas; continuation of the GEHC agreement and the risk factors reported from
time to time in the Company's SEC reports, including its recent report on Form
10-K. The Company undertakes no obligation to update forward-looking statements
as a result of future events or developments.
Unless the context requires otherwise, all references to "we", "our", "us",
"Company", "registrant", "Vaso" or "management" refer to Vaso Corporation and
its subsidiaries
General Overview
COVID-19 Pandemic
The COVID-19 pandemic has had and will continue to have a significant impact on
the economy of the United States and the world, and it is anticipated that its
negative impact to the Company's financial condition and results of operations
will continue. At this time, we cannot reasonably estimate what the total impact
may be. The pandemic has resulted in workforce and travel restrictions and
created business disruptions in supply chain, production and demand across many
business sectors. For Vaso Corporation, we believe that significant uncertainty
will continue to remain in all our businesses for the remainder of 2022 and
beyond.
We have taken significant steps in our efforts to protect our workforce and our
clients. Many of our employees have been working remotely and we are
implementing plans to reopen our work sites consistent with the guidelines
promulgated by the CDC and respective state governments. In addition, the
Company received a $3.6 million loan under the Paycheck Protection Program of
the CARES Act. This loan was used to principally cover our payroll costs for a
period of time as specified by the rules, thereby allowing us to maintain our
workforce and continue to provide services and solutions to our clients. In June
2021, the loan, as well as accrued interest, was forgiven in its entirety by the
Small Business Administration.
Our Business Segments
Vaso Corporation ("Vaso") was incorporated in Delaware in July 1987. We
principally operate in three distinct business segments in the healthcare and
information technology industries. We manage and evaluate our operations, and
report our financial results, through these three business segments.
· IT segment, operating through a wholly-owned subsidiary VasoTechnology,
Inc., primarily focuses on healthcare IT and managed network technology
services;
· Professional sales service segment, operating through a wholly-owned
subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses
on the sale of healthcare capital equipment for GEHC into the healthcare
provider middle market; and
· Equipment segment, operating through a wholly-owned subsidiary
VasoMedical, Inc., primarily focuses on the design, manufacture, sale and
service of proprietary medical devices.
Page 18
Table of Contents
Vaso Corporation and Subsidiaries
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations
are based upon the accompanying unaudited condensed consolidated financial
statements, which have been prepared in accordance with accounting principles
generally accepted in the United States ("U.S. GAAP"). The preparation of
financial statements in conformity with U.S. GAAP requires management to make
judgments, estimates and assumptions that affect the reported amounts of assets,
liabilities, revenue, expenses, and the related disclosures at the date of the
financial statements and during the reporting period. Although these estimates
are based on our knowledge of current events, our actual amounts and results
could differ from those estimates. The estimates made are based on historical
factors, current circumstances, and the experience and judgment of our
management, who continually evaluate the judgments, estimates and assumptions
and may employ outside experts to assist in the evaluations.
Certain of our accounting policies are deemed "critical", as they are both most
important to the financial statement presentation and require management's most
difficult, subjective or complex judgments as a result of the need to make
estimates about the effect of matters that are inherently uncertain. For a
discussion of our critical accounting policies, see Note B to the condensed
consolidated financial statements and "Management's Discussion and Analysis of
Financial Condition and Results of Operations" in our Annual Report on Form 10-K
for the year ended December 31, 2021 as filed with the SEC on March 31, 2022.
Results of Operations - For the Three Months Ended June 30, 2022 and 2021
Revenues
Total revenue for the three months ended June 30, 2022 and 2021 was $19,502,000
and $16,131,000, respectively, representing an increase of $3,371,000, or 21%
year-over-year. On a segment basis, revenue in the professional sales services
segment increased $3,883,000 while revenue in the IT and equipment segments
decreased $423,000 and $89,000, respectively.
Revenue in the IT segment for the three months ended June 30, 2022 was
$10,019,000 compared to $10,442,000 for the three months ended June 30, 2021, a
decrease of $423,000, or 4%, of which $481,000 resulted from lower NetWolves
revenues, partially offset by $58,000 higher revenues in the healthcare IT
business. Our monthly recurring revenue in the IT segment accounted for
$9,075,000 or 91% of the segment revenue in the second quarter of 2022, and
$9,246,000 or 89% of the segment revenue for the same quarter last year (see
Note C).
Commission revenues in the professional sales service segment were $8,854,000 in
the second quarter of 2022, an increase of $3,883,000, or 78%, as compared to
$4,971,000 in the same quarter of 2021. The increase in commission revenues was
due primarily to both an increase in the volume of underlying equipment
delivered by GEHC during the period and a higher blended commission rate
applicable to such deliveries. The Company only recognizes commission revenue
when the underlying equipment has been accepted at the customer site in
accordance with the specific terms of the sales agreement. Consequently, amounts
billable, or billed and received, under the agreement with GE Healthcare prior
to customer acceptance of the equipment are recorded as deferred revenue in the
condensed consolidated balance sheet. As of June 30, 2022, $27,090,000 in
deferred commission revenue was recorded in the Company's condensed consolidated
balance sheet, of which $8,511,000 was long-term. As of June 30, 2021,
$19,655,000 in deferred commission revenue was recorded in the Company's
condensed consolidated balance sheet, of which $7,046,000 was long-term. The
increase in deferred revenue is principally due to an increase in new orders
booked.
Revenue in the equipment segment decreased by $89,000, or 12%, to $629,000 for
the three-month period ended June 30, 2022 from $718,000 for the same period of
the prior year, principally due to lower equipment revenues in China as impacted
by the COVID-19 lockdown.
Gross Profit
Gross profit for the three months ended June 30, 2022 and 2021 was $11,336,000,
or 58% of revenue, and $8,640,000, or 54% of revenue, respectively, representing
an increase of $2,696,000, or 31% year-over-year. On a segment basis, gross
profit in the professional sales service segment increased $3,204,000, or 81%,
while gross profit in the IT and equipment segments decreased $417,000, or 10%;
and $91,000, or 16%, respectively.
Page 19
Table of Contents
Vaso Corporation and Subsidiaries
IT segment gross profit for the three months ended June 30, 2022 was $3,677,000,
or 37% of the segment revenue, compared to $4,094,000, or 39% of the segment
revenue for the three months ended June 30, 2021. The year-over-year decrease of
$417,000, or 10%, was primarily a result of lower sales volume in the NetWolves
business, partially offset by higher sales volume and higher margin sales mix in
the healthcare IT business.
Professional sales service segment gross profit was $7,180,000, or 81% of
segment revenue, for the three months ended June 30, 2022 as compared to
$3,976,000, or 80% of the segment revenue, for the three months ended June 30,
2021, reflecting an increase of $3,204,000, or 81%. The increase in absolute
dollars was primarily due to higher commission revenue as a result of a higher
blended commission rate and higher volume of GEHC equipment delivered during the
second quarter of 2022 than in the same period last year. Cost of commissions in
the professional sales service segment of $1,674,000 and $995,000, for the three
months ended June 30, 2022 and 2021, respectively, reflected commission expense
associated with recognized commission revenues.
Commission expense associated with short-term deferred revenue is recorded as
short-term deferred commission expense, or with long-term deferred revenue as
part of other assets, on the balance sheet until the related commission revenue
is recognized.
Equipment segment gross profit decreased to $479,000, or 76% of segment
revenues, for the second quarter of 2022 compared to $570,000, or 79% of segment
revenues, for the same quarter of 2021. The $91,000, or 16%, decrease in gross
profit was the result of lower equipment revenue during the quarter compounded
with higher material and labor costs.
Operating Income (Loss)
Operating income (loss) for the three months ended June 30, 2022 and 2021 was
$1,562,000 and $(722,000), respectively, representing an increase of $2,284,000,
due primarily to the increase in gross profit. On a segment basis, the IT
segment recorded an operating loss of $918,000 in the second quarter of 2022 as
compared to an operating loss of $246,000 in the same period of 2021; the
equipment segment recorded an operating loss of $77,000 in the second quarter of
2022 as compared to an operating loss of $128,000 in the same period of 2021;
and the professional sales service segment recorded operating income of
$2,754,000 in the second quarter of 2022 as opposed to an operating loss of
$47,000 in the same period of 2021.
Operating loss in the IT segment increased to $918,000 for the three-month
period ended June 30, 2022 as compared to an operating loss of $246,000 in the
same period of 2021, due to lower gross profit and higher selling, general, and
administrative ("SG&A") costs. Operating income in the professional sales
service segment increased by $2,801,000 to $2,754,000 in the three-month period
ended June 30, 2022 as compared to a $47,000 operating loss in the same period
of 2021, due to higher gross profit partially offset by higher SG&A costs. The
equipment segment reported an operating loss of $77,000 in the second quarter of
2022, compared to an operating loss of $128,000 in the second quarter 2021, an
improvement of $51,000. The decrease in operating loss was due to lower SG&A and
R&D costs partially offset by lower gross profit.
SG&A costs for the three months ended June 30, 2022 and 2021 were $9,604,000 and
$9,192,000, respectively, representing an increase of $412,000, or 5%
year-over-year. On a segment basis, SG&A costs in the IT segment increased by
$257,000 in the second quarter of 2022 from the same quarter of the prior year
due to higher personnel costs; SG&A costs in the professional sales service
segment increased $403,000 due mainly to higher travel and personnel costs; and
SG&A costs in the equipment segment decreased $142,000 due mainly to lower
marketing and personnel costs. Corporate costs not allocated to segments
decreased $106,000 due mainly to lower accounting and director fees.
Research and development ("R&D") expenses were $170,000, or 1% of revenues, for
the second quarters of both 2021 and 2022.
Page 20
Table of Contents
Vaso Corporation and Subsidiaries
Adjusted EBITDA
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation
and amortization), which is a non-GAAP financial measure, as net income (loss),
plus interest expense (income), net; tax expense; depreciation and amortization;
and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric
that is used by the investment community for comparative and valuation purposes.
We disclose this metric in order to support and facilitate the dialogue with
research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and
should not be considered a substitute for operating income, which we consider to
be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has
limitations as an analytical tool, and when assessing our operating performance,
you should not consider Adjusted EBITDA in isolation, or as a substitute for net
income or other consolidated income statement data prepared in accordance with
U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do,
limiting its usefulness as a comparative measure.
A reconciliation of net income to Adjusted EBITDA is set forth below:
(in thousands)
Three months ended June 30,
2022 2021
(unaudited) (unaudited)
Net income $ 1,495 $ 2,780
Interest expense (income), net 5 78
Income tax expense 18 50
Depreciation and amortization 805 528
Share-based compensation 6 8
Adjusted EBITDA $ 2,329 $ 3,444Adjusted EBITDA decreased by $1,115,000, to $2,329,000 in the quarter ended June
30, 2022 from $3,444,000 in the quarter ended June 30, 2021. The decrease was
attributable mainly to the decrease in net income arising from the non-recurring
$3,646,000 gain on forgiveness of the PPP loan and interest in the second
quarter of 2021, partially offset by the increase in depreciation and
amortization.
Interest and Other Income (Expense)
Interest and other income (expense) for the three months ended June 30, 2022 was
$(49,000) as compared to $3,552,000 for the corresponding period of 2021. The
decrease in interest and other income (expense) was due primarily to the
non-recurring $3,646,000 gain on forgiveness of the PPP loan and interest in the
three months ended June 30, 2021.
Income Tax Expense
For the three months ended June 30, 2022, we recorded income tax expense of
$18,000 as compared to $50,000 for the corresponding period of 2021. The $32,000
decrease arose mainly from lower tax expense in our China operations.
Net Income
Net income for the three months ended June 30, 2022 was $1,495,000 as compared
to net income of $2,780,000 for the three months ended June 30, 2021,
representing a decrease of $1,285,000. Income per share of $0.01 and $0.02 was
recorded in the three-month periods ended June 30, 2022 and 2021, respectively.
The principal cause of the decrease in net income is because the Company
recorded the PPP loan forgiveness in the three months ended June 30, 2021,
partially offset by higher operating income in the current year quarter.
Page 21
Table of Contents
Vaso Corporation and Subsidiaries
Results of Operations - For the Six Months Ended June 30, 2022 and 2021
Revenues
Total revenue for the six months ended June 30, 2022 and 2021 was $36,512,000
and $32,651,000, respectively, representing an increase of $3,861,000, or 12%
year-over-year. On a segment basis, revenue in the professional sales service
segment increased $5,835,000 while revenue in the IT and equipment segments
decreased $1,674,000 and $300,000, respectively.
Revenue in the IT segment for the six months ended June 30, 2022 was $20,022,000
compared to $21,696,000 for the six months ended June 30, 2021, a decrease of
$1,674,000, or 8%, of which $1,572,000 resulted from lower NetWolves revenue and
$102,000 from lower healthcare IT revenue. Our monthly recurring revenue in the
IT segment accounted for $18,309,000 or 91% of the segment revenue in the first
half of 2022, and $19,271,000 or 89% of the segment revenue for the same period
last year (see Note C).
Commission revenues in the professional sales service segment were $15,461,000
in the first half of 2022, an increase of $5,835,000, or 61%, as compared to
$9,626,000 in the first half of 2021. The increase in commission revenues was
due primarily to both an increase in the volume of underlying equipment
delivered by GEHC during the period and a higher blended commission rate
applicable to such deliveries. The Company recognizes commission revenue when
the underlying equipment has been accepted at the customer site in accordance
with the specific terms of the sales agreement. Consequently, amounts billable,
or billed and received, under the agreement with GE Healthcare prior to customer
acceptance of the equipment are recorded as deferred revenue in the condensed
consolidated balance sheet. As of June 30, 2022, $27,090,000 in deferred
commission revenue was recorded in the Company's condensed consolidated balance
sheet, of which $8,511,000 was long-term. As of June 30, 2021, $19,655,000 in
deferred commission revenue was recorded in the Company's condensed consolidated
balance sheet, of which $7,046,000 was long-term. The increase in deferred
revenue is principally due to an increase in new orders booked.
Revenue in the equipment segment decreased by $300,000, or 23%, to $1,029,000
for the six-month period ended June 30, 2022 from $1,329,000 for the same period
of the prior year, principally due to lower equipment deliveries in our China
operations.
Gross Profit
Gross profit for the six months ended June 30, 2022 and 2021 was $21,105,000, or
58% of revenue, and $17,200,000, or 53% of revenue, respectively, representing
an increase of $3,905,000, or 23% year-over-year. On a segment basis, gross
profit in the professional sales service increased $4,845,000, or 63%, while
gross profit in the IT and equipment segments decreased $690,000, or 8%, and
$250,000, or 24%, respectively.
IT segment gross profit for the six months ended June 30, 2022 was $7,811,000,
or 39% of the segment revenue, compared to $8,501,000, or 39% of the segment
revenue for the six months ended June 30, 2021. The year-over-year decrease of
$690,000, or 8%, was primarily a result of lower revenues at NetWolves,
partially offset by higher margin sales mix in the healthcare IT business.
Professional sales service segment gross profit was $12,486,000, or 81% of
segment revenue, for the six months ended June 30, 2022 as compared to
$7,641,000, or 79% of the segment revenue, for the six months ended June 30,
2021, reflecting an increase of $4,845,000, or 63%. The increase in absolute
dollars was primarily due to higher commission revenue as a result of a higher
blended commission rate and higher volume of GEHC equipment delivered during the
first half of 2022 than in the same period last year. Cost of commissions in the
professional sales service segment of $2,975,000 and $1,985,000, for the six
months ended June 30, 2022 and 2021, respectively, reflected commission expense
associated with recognized commission revenues.
Commission expense associated with short-term deferred revenue is recorded as
short-term deferred commission expense, or with long-term deferred revenue as
part of other assets, on the balance sheet until the related commission revenue
is recognized.
Equipment segment gross profit decreased to $808,000, or 79% of segment
revenues, for the first half of 2022 compared to $1,058,000, or 80% of segment
revenues, for the same half of 2021. The $250,000, or 24%, decrease in gross
profit was primarily the result of a decrease in equipment sales and an increase
in material and labor costs in our China operations during the first half of
2022.
Page 22
Table of Contents
Vaso Corporation and Subsidiaries
Operating Income (Loss)
Operating income (loss) for the six months ended June 30, 2022 and 2021 was
$1,207,000 and $(1,262,000), respectively, representing an improvement of
$2,469,000, due primarily to higher gross profit, partially offset by higher
SG&A costs. On a segment basis, the IT segment recorded an operating loss of
$1,057,000 in the first half of 2022 as compared to an operating loss of
$179,000 in the same period of 2021; the professional sales service segment
recorded operating income of $2,990,000 in the first half of 2022 as compared to
an operating loss of $382,000 in the same period of 2021; and the equipment
segment recorded an operating loss of $156,000 in the first half of 2022 as
compared to an operating loss of $115,000 in the same period of 2021 .
Operating loss in the IT segment increased to $1,057,000 for the six-month
period ended June 30, 2022 as compared to an operating loss of $179,000 in the
same period of 2021, due to lower gross profit and higher selling, general, and
administrative ("SG&A") costs. The professional sales service segment reported
operating income of $2,990,00 in the first half of 2022, an increase of
$3,372,000 from an operating loss of $382,000 in the six-month period ended June
30, 2021, due to higher gross profit partially offset by higher SG&A costs. The
equipment segment reported an operating loss of $156,000 in the first half of
2022, compared to an operating loss of $115,000 in the first half 2021, an
increase of $41,000 due to lower gross profit, partially offset offset by lower
SG&A costs.
SG&A costs for the six months ended June 30, 2022 and 2021 were $19,606,000 and
$18,148,000, respectively, representing an increase of $1,458,000, or 8%
year-over-year. On a segment basis, SG&A costs in the IT segment increased by
$243,000 in the first half of 2022 from the same half of the prior year due to
higher personnel costs; SG&A costs in the professional sales service segment
increased by $1,472,000 due to higher travel and personnel costs; and SG&A costs
in the equipment segment decreased by $240,000 due mainly to lower personnel
costs. Corporate costs not allocated to segments decreased $17,000 due mainly to
lower accounting and director fees.
Research and development ("R&D") expenses were $292,000, or 1% of revenues, for
the first half of 2022, a decrease of $22,000, or 7%, from $314,000, or 1% of
revenues, for the first half of 2021. The decrease is primarily attributable to
lower product development expenses in the IT segment.
Adjusted EBITDA
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation
and amortization), which is a non-GAAP financial measure, as net income (loss),
plus interest expense (income), net; tax expense; depreciation and amortization;
and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric
that is used by the investment community for comparative and valuation purposes.
We disclose this metric in order to support and facilitate the dialogue with
research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and
should not be considered a substitute for operating income, which we consider to
be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has
limitations as an analytical tool, and when assessing our operating performance,
you should not consider Adjusted EBITDA in isolation, or as a substitute for net
income or other consolidated income statement data prepared in accordance with
U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do,
limiting its usefulness as a comparative measure.
Page 23
Table of Contents
Vaso Corporation and Subsidiaries
A reconciliation of net income to Adjusted EBITDA is set forth below:
(in thousands)
Six months ended June 30,
2022 2021
(unaudited) (unaudited)
Net income $ 1,151 $ 2,137
Interest expense (income), net 24 199
Income tax expense 30 68
Depreciation and amortization 1,258 1,124
Share-based compensation 13 17
Adjusted EBITDA $ 2,476 $ 3,545Adjusted EBITDA decreased by $1,069,000 to $2,476,000 in the period ended June
30, 2022 from $3,545,000 in the period ended June 30, 2021. The decrease was
primarily attributable to the $3,646,000 non-recurring gain on PPP loan and
interest forgiveness in the six months ended June 30, 2021, partially offset by
higher depreciation and amortization.
Interest and Other Income (Expense)
Interest and other income (expense) for the six months ended June 30, 2022 was
$(26,000) as compared to $3,467,000 for the corresponding period of 2021. The
decrease in interest and other income was due primarily to the PPP loan and
interest forgiveness in the six months ended June 30, 2021.
Income Tax Expense
We recorded income tax expense of $30,000 and $68,000 for the six-month periods
ended June 30, 2022 and 2021, respectively. The decrease arose mainly from lower
tax expense in our China operations.
Net Income
Net income for the six months ended June 30, 2022 was $1,151,000 as compared to
net income of $2,137,000 for the six months ended June 30, 2021, representing a
decrease of $986,000, or 46%. Income per share of $0.01 was recorded in the
six-month periods ended June 30, 2022 and 2021, respectively. The principal
cause of the decrease in net income is the PPP loan forgiveness in the six
months ended June 30, 2021, partially offset by higher operating results in the
six months ended June 30, 2022.
Liquidity and Capital Resources
Cash and Cash Flow
We have financed our operations from working capital. At June 30, 2022, we had
cash and cash equivalents of $15,436,000 and negative working capital of
$1,483,000, compared to cash and cash equivalents of $6,025,000 and negative
working capital of $3,197,000 at December 31, 2021. $15,007,000 in negative
working capital at June 30, 2022 is attributable to the net balance of deferred
commission expense and deferred revenue. These are non-cash expense and revenue
items and have no impact on future cash flows.
Page 24
Table of Contents
Vaso Corporation and Subsidiaries
Cash provided by operating activities was $9,731,000, which consisted of net
income after adjustments to reconcile net income to net cash of $2,634,000 and
cash provided by operating assets and liabilities of $7,097,000, during the six
months ended June 30, 2022, compared to cash provided by operating activities of
$5,593,000 for the same period in 2021. The changes in the account balances
primarily reflect a decrease in accounts and other receivables of $8,376,000 and
an increase in deferred revenue of $2,132,000, partially offset by decreases in
accrued commissions, accrued expenses, and accounts payable of $1,040,000,
$941,000 and $628,000, respectively.
Cash used in investing activities during the six-month period ended June 30,
2022 was $204,000 attributed to $358,000 used for the purchase of equipment and
software, offset by the redemption of $154,000 in short-term investments.
Cash used in financing activities during the six-month period ended June 30,
2022 was $125,000 for the repayment of notes payable and finance lease
obligations.
Liquidity
The Company expects to generate sufficient cash flow from operations to satisfy
its obligations for at least the next twelve months.
It is anticipated that the COVID-19 pandemic may continue to adversely impact
our operations during and beyond the remaining quarters of 2022, depending on
the duration of the pandemic and the timing and success of the continued
reopening of the economy.
Page 25
Table of Contents
Vaso Corporation and Subsidiaries© Edgar Online, source Glimpses
VASO CORPORATION 
